A Phase 3 interventional study of Triptorelin (I.N.N.) in Precocious Puberty, sponsored by Ipsen. Completed at 10 sites in France. Per ClinicalTrials.gov, last updated 2019-01-15.
Sponsored by Ipsen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the protocol is to assess the efficacy of triptorelin 11.25 mg with respect to the proportion of children who maintain a regression or stabilisation of sexual maturity until the end of the study.
75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.
This study's enrollment of 35 is below the median of 64 across 47 interventional studies indexed under Puberty, Precocious.
Browse Puberty, Precocious studies →Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Triptorelin (I.N.N.)
Decapeptyl® SR 11.25mg
Percentage of Children With a Stabilisation or Regression of Tanner Pubertal Stage at the End of the Study (Final Visit), Compared to Pretreatment (Month -6) and Baseline (Month 0)
The primary objective was to assess efficacy of triptorelin pamoate 11.25 mg with respect to percentage of children maintaining a regression or stabilisation of sexual maturity (based on Tanner breast \[girls\] or genital \[boys\] pubertal stage) until end of study. Study treatment lasted until end of the therapeutic period; visits for Months 36 and 48 were optional since a child may have already finished the study at a prior visit. The Final Visit only occurred if the child did not end the study by a complete visit such as at Months 24, 36 or 48. Results are presented only for percentage of girls with regression or stabilisation of Tanner breast pubertal stage (n=34). Since only one boy was included in the study, results for this outcome measure were listed only and no statistical analysis was performed. Please also note additional post-hoc analysis for regression or stabilisation of Tanner breast pubertal stage which applied the variable Last Visit on Treatment instead of Final Visit.
Time frame: Months 12, 24, 36, 48 and Final Visit (if applicable; up to 63 months)
Percentage of Patients With a Suppressed Luteinizing Hormone (LH) Response to Gonadotropin-Releasing Hormone (GnRH) Test
A suppressed LH response to the GnRH test was defined as a stimulated peak of LH ≤3 international units per litre (IU/L). Percentage of patients who had a suppressed LH response to the GnRH test is reported. It should be noted that almost no hormonal data was collected after Baseline; all data analysed is presented.
Time frame: Months -6, 0 and 36
Levels of Oestradiol in Girls or Testosterone in Boys Both Measured by Radioimmunoassay (RIA)
Mean levels of oestradiol in girls or testosterone in boys are reported. It should be noted that almost no hormonal data was collected after Baseline; all data analysed is presented.
Time frame: Months -6, 0, 12, 36 and Final Visit (up to 63 months)
Percentage of Patients With a Suppressed Follicle Stimulating Hormone (FSH) Response to GnRH Test
A suppressed FSH response to the GnRH test was defined as a stimulated peak of FSH ≤3 IU/L. Percentage of patients who had a suppressed FSH response to the GnRH test is reported. It should be noted that almost no hormonal data was collected after Baseline; all data analysed is presented.
Time frame: Months -6, 0 and 36
Body Mass Index (BMI) for Chronological Age Variation
Mean changes of BMI from Pretreatment and from Baseline are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
Time frame: Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months)
BMI Standard Deviation (SD) Score for Chronological Age Variation
Mean changes of BMI SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
Time frame: Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months)
Auxological Parameters Variations: Height SD Score
Mean changes of height SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
Time frame: Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months)
Auxological Parameters Variations: Growth Velocity SD Score
Mean changes of growth velocity SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
Time frame: Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months)
Auxological Parameters Variations: Weight Variation
Mean changes of weight from Pretreatment and from Baseline are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
Time frame: Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months)
Predicted Adult Height SD Score
Mean change of predicted adult height SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented. Also note that data for this endpoint was analysed for girls only.
Time frame: Months -6, 0, 12 and Final Visit (up to 63 months)
Bone Age Maturation
Mean change in difference between bone age and chronological age from Pretreatment and from Baseline are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
Time frame: Months -6, 0 and Final Visit (up to 63 months)
Percentage of Girls With a Uterine Length < 36 Millimetres (mm)
Percentage of girls who had a uterine length \< 36 mm are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
Time frame: Months -6, 0, 12, 24, 36 and Final Visit (up to 63 months)
Percentage of Children With a Stabilisation or Regression of Tanner Pubic Hair Pubertal Stage at the End of the Study (Final Visit), Compared to Pretreatment (Month -6) and Baseline (Month 0)
Pubic hair was measured by the Tanner method on a scale of 1 to 6. A low grade (i.e. 1) corresponds to a pre-pubertal stage and a high grade (i.e. 5 or 6) to an adult stage. Percentage of patients who had stabilisation or regression (no change in grade or a reduced grade) of Tanner pubic hair pubertal stage is reported. Study treatment was to last until the end of the therapeutic period; visits for Months 36 and 48 were optional because if the girl was already 11 and the boy already 13, they would have finished the study at a prior visit. The Final Visit was to occur only if the child did not end the study by a complete visit such as at Months 24, 36 or 48. Please also note the additional post-hoc analysis for percentage of children with a stabilisation or regression of Tanner pubic hair pubertal stage which applied the variable Last Visit on Treatment instead of Final Visit.
Time frame: Months 12, 24, 36, 48 and Final Visit (if applicable; up to 63 months)
The study was designed as a multicentre study and included 10 investigational sites in France. This follow up study was to start on the day of the last visit (Month 6) of the phase III 2-54-52014-143 study and was to end when the Investigator judged that the patient had completed his/her treatment, i.e. at around 11 years in girls and 13 in boys.
| Milestone | Triptorelin Pamoate 11.25 mg |
|---|---|
| Started | 35 |
| Completed | 31 |
| Not completed | 4 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Lost to follow-up | 2 |
The primary objective was to assess efficacy of triptorelin pamoate 11.25 mg with respect to percentage of children maintaining a regression or stabilisation of sexual maturity (based on Tanner breast \[girls\] or genital \[boys\] pubertal stage) until end of study. Study treatment lasted until end of the therapeutic period; visits for Months 36 and 48 were optional since a child may have already finished the study at a prior visit. The Final Visit only occurred if the child did not end the study by a complete visit such as at Months 24, 36 or 48. Results are presented only for percentage of girls with regression or stabilisation of Tanner breast pubertal stage (n=34). Since only one boy was included in the study, results for this outcome measure were listed only and no statistical analysis was performed. Please also note additional post-hoc analysis for regression or stabilisation of Tanner breast pubertal stage which applied the variable Last Visit on Treatment instead of Final Visit.
| percentage of patients | Triptorelin Pamoate 11.25 mg |
|---|---|
| Compared to Pretreatment (Month -6) | 61.8 (43.56 to 77.83) |
| Compared to Baseline (Month 0) | 52.9 (35.13 to 70.22) |
A suppressed LH response to the GnRH test was defined as a stimulated peak of LH ≤3 international units per litre (IU/L). Percentage of patients who had a suppressed LH response to the GnRH test is reported. It should be noted that almost no hormonal data was collected after Baseline; all data analysed is presented.
| percentage of patients | Triptorelin Pamoate 11.25 mg |
|---|---|
| Pretreatment (Month -6) | 0 (NA to NA) |
| Baseline (Month 0) | 91.4 (76.94 to 98.20) |
| Month 36 | 100 (2.50 to 100.00) |
Mean levels of oestradiol in girls or testosterone in boys are reported. It should be noted that almost no hormonal data was collected after Baseline; all data analysed is presented.
| picograms per millilitre (pg/mL) | Triptorelin Pamoate 11.25 mg |
|---|---|
| Oestradiol at Pretreatment (Girls) | 18.59 ± 9.79 |
| Oestradiol at Baseline (Girls) | 8.71 ± 4.51 |
| Oestradiol at Month 12 (Girls) | 2.50 ± NA |
| Oestradiol at Month 36 (Girls) | 12.20 ± NA |
| Oestradiol at Final Visit (Girls) | 10.00 ± NA |
| Testosterone at Pretreatment (Boy) | 6.80 ± NA |
| Testosterone at Baseline (Boy) | 0.56 ± NA |
A suppressed FSH response to the GnRH test was defined as a stimulated peak of FSH ≤3 IU/L. Percentage of patients who had a suppressed FSH response to the GnRH test is reported. It should be noted that almost no hormonal data was collected after Baseline; all data analysed is presented.
| percentage of patients | Triptorelin Pamoate 11.25 mg |
|---|---|
| Pretreatment (Month -6) | 0 (NA to NA) |
| Baseline (Month 0) | 82.9 (66.35 to 93.44) |
| Month 36 | 0 (NA to NA) |
Mean changes of BMI from Pretreatment and from Baseline are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
| kilograms per metre squared (kg/m^2) | Triptorelin Pamoate 11.25 mg |
|---|---|
| Change from Pretreatment at Baseline | 0.43 ± 0.74 |
| Change from Pretreatment at Month 12 | 1.60 ± 1.29 |
| Change from Pretreatment at Month 24 | 1.69 ± 1.60 |
| Change from Pretreatment at Month 36 | 1.69 ± 2.48 |
| Change from Pretreatment at Month 48 | 1.06 ± 1.29 |
| Change from Pretreatment at Final Visit | 2.39 ± 1.62 |
| Change from Baseline at Month 12 | 1.14 ± 1.00 |
| Change from Baseline at Month 24 | 1.43 ± 1.45 |
| Change from Baseline at Month 36 | 1.53 ± 1.62 |
| Change from Baseline at Month 48 | 1.34 ± 0.73 |
| Change from Baseline at Final Visit | 1.91 ± 1.50 |
Mean changes of BMI SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
| SD score | Triptorelin Pamoate 11.25 mg |
|---|---|
| Change from Pretreatment at Baseline | 0.06 ± 0.27 |
| Change from Pretreatment at Month 12 | 0.16 ± 0.37 |
| Change from Pretreatment at Month 24 | -0.01 ± 0.37 |
| Change from Pretreatment at Month 36 | -0.04 ± 0.63 |
| Change from Pretreatment at Month 48 | -0.27 ± 0.68 |
| Change from Pretreatment at Final Visit | 0.10 ± 0.46 |
| Change from Baseline at Month 12 | 0.09 ± 0.27 |
| Change from Baseline at Month 24 | -0.03 ± 0.27 |
| Change from Baseline at Month 36 | -0.04 ± 0.38 |
| Change from Baseline at Month 48 | -0.15 ± 0.45 |
| Change from Baseline at Final Visit | 0.01 ± 0.36 |
Mean changes of height SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
| SD score | Triptorelin Pamoate 11.25 mg |
|---|---|
| Change from Pretreatment at Baseline | 0.09 ± 0.14 |
| Change from Pretreatment at Month 12 | -0.05 ± 0.25 |
| Change from Pretreatment at Month 24 | -0.24 ± 0.43 |
| Change from Pretreatment at Month 36 | -0.83 ± 1.00 |
| Change from Pretreatment at Month 48 | -1.68 ± 0.43 |
| Change from Pretreatment at Final Visit | -0.36 ± 0.53 |
| Change from Baseline at Month 12 | -0.12 ± 0.22 |
| Change from Baseline at Month 24 | -0.27 ± 0.43 |
| Change from Baseline at Month 36 | -0.96 ± 0.74 |
| Change from Baseline at Month 48 | -1.65 ± 0.38 |
| Change from Baseline at Final Visit | -0.43 ± 0.50 |
Mean changes of growth velocity SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
| SD score | Triptorelin Pamoate 11.25 mg |
|---|---|
| Change from Pretreatment at Baseline | -1.85 ± 2.10 |
| Change from Pretreatment at Month 12 | -2.44 ± 2.08 |
| Change from Pretreatment at Month 24 | -3.18 ± 2.76 |
| Change from Pretreatment at Month 36 | -6.97 ± 5.85 |
| Change from Pretreatment at Month 48 | -6.96 ± 5.79 |
| Change from Pretreatment at Final Visit | -2.70 ± 2.47 |
| Change from Baseline at Month 12 | -1.06 ± 1.44 |
| Change from Baseline at Month 24 | -0.92 ± 1.50 |
| Change from Baseline at Month 36 | -2.79 ± 1.18 |
| Change from Baseline at Month 48 | -2.65 ± 1.01 |
| Change from Baseline at Final Visit | -1.09 ± 1.30 |
Mean changes of weight from Pretreatment and from Baseline are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
| kg | Triptorelin Pamoate 11.25 mg |
|---|---|
| Change from Pretreatment at Baseline | 2.49 ± 1.53 |
| Change from Pretreatment at Month 12 | 7.56 ± 3.47 |
| Change from Pretreatment at Month 24 | 10.13 ± 4.34 |
| Change from Pretreatment at Month 36 | 12.70 ± 7.05 |
| Change from Pretreatment at Month 48 | 12.20 ± 1.70 |
| Change from Pretreatment at Final Visit | 13.17 ± 6.21 |
| Change from Baseline at Month 12 | 5.06 ± 2.79 |
| Change from Baseline at Month 24 | 8.21 ± 4.17 |
| Change from Baseline at Month 36 | 10.27 ± 5.11 |
| Change from Baseline at Month 48 | 10.85 ± 0.92 |
| Change from Baseline at Final Visit | 10.65 ± 6.02 |
Mean change of predicted adult height SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented. Also note that data for this endpoint was analysed for girls only.
| SD score | Triptorelin Pamoate 11.25 mg |
|---|---|
| Change from Pretreatment at Baseline | 0.31 ± 0.18 |
| Change from Pretreatment at Month 12 | 0.82 ± NA |
| Change from Pretreatment at Final Visit | 2.13 ± 0.87 |
| Change from Baseline at Final Visit | 1.83 ± 0.64 |
Mean change in difference between bone age and chronological age from Pretreatment and from Baseline are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
| years | Triptorelin Pamoate 11.25 mg |
|---|---|
| Change from Pretreatment at Baseline | -0.16 ± 0.53 |
| Change from Pretreatment at Final Visit | -1.61 ± 1.04 |
| Change from Baseline at Final Visit | -1.69 ± 0.85 |
Percentage of girls who had a uterine length \< 36 mm are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
| percentage of patients | Triptorelin Pamoate 11.25 mg |
|---|---|
| Pretreatment | 42.4 (25.48 to 60.78) |
| Baseline | 41.2 (24.65 to 59.30) |
| Month 12 | 16.7 (0.42 to 64.12) |
| Month 24 | 50.0 (6.76 to 93.24) |
| Month 36 | 0 (NA to NA) |
| Final Visit | 25.0 (0.63 to 80.59) |
Pubic hair was measured by the Tanner method on a scale of 1 to 6. A low grade (i.e. 1) corresponds to a pre-pubertal stage and a high grade (i.e. 5 or 6) to an adult stage. Percentage of patients who had stabilisation or regression (no change in grade or a reduced grade) of Tanner pubic hair pubertal stage is reported. Study treatment was to last until the end of the therapeutic period; visits for Months 36 and 48 were optional because if the girl was already 11 and the boy already 13, they would have finished the study at a prior visit. The Final Visit was to occur only if the child did not end the study by a complete visit such as at Months 24, 36 or 48. Please also note the additional post-hoc analysis for percentage of children with a stabilisation or regression of Tanner pubic hair pubertal stage which applied the variable Last Visit on Treatment instead of Final Visit.
| percentage of patients | Triptorelin Pamoate 11.25 mg |
|---|---|
| Compared to Pretreatment (Month -6) | 31.4 (16.85 to 49.29) |
| Compared to Baseline (Month 0) | 37.1 (21.47 to 55.08) |
One primary efficacy endpoint was to assess efficacy of triptorelin pamoate 11.25 mg with respect to percentage of girls maintaining a regression or stabilisation of sexual maturity (based on Tanner breast pubertal stage) until end of study. Results reported for this primary endpoint applied the variable 'Final Visit' for comparison to Pretreatment and Baseline. Since it was determined that the majority of patients had a Final Visit \>3 months after their last injection, a post-hoc analysis of the percentage of girls with regression or stabilisation of Tanner breast pubertal stage was performed which applied the derived variable 'Last Visit on Treatment' to compare to the Pretreatment stage and to Baseline. This post-hoc analysis was judged to be appropriate since triptorelin pamoate 3-month formulation allows release of the active compound over 3 months and beyond this time, pubertal development is expected to progress.
| percentage of patients | Triptorelin Pamoate 11.25 mg |
|---|---|
| Compared to Pretreatment (Month -6) | 91.2 (76.32 to 98.14) |
| Compared to Baseline (Month 0) | 91.2 (76.32 to 98.14) |
One secondary efficacy endpoint in this study was the percentage of children who had stabilisation or regression (no change in grade or a reduced grade) of Tanner pubic hair pubertal stage at the end of the study. Results reported for this secondary endpoint applied the variable 'Final Visit' for comparison to Pretreatment and Baseline. Since it was determined that the majority of patients had a Final Visit \>3 months after their last injection, a post-hoc analysis of the percentage of children with regression or stabilisation of Tanner pubic hair pubertal stage was performed which applied the derived variable 'Last Visit on Treatment' for comparison to the Pretreatment stage. This post-hoc analysis was judged to be appropriate since triptorelin pamoate 3-month formulation allows release of the active compound over 3 months and beyond this time, pubertal development is expected to progress.
| percentage of patients | Triptorelin Pamoate 11.25 mg |
|---|---|
| Percentage of Children With a Stabilisation or Regression of Tanner Pubic Hair Pubertal Stage at the End of the Study (Last Visit on Treatment), Compared to Pretreatment (Month -6) | 57.1 |
Collected over Up to 51 months (up to 48 months treatment + 3 months follow up). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Triptorelin Pamoate 11.25 mg | — | 3/35 (8.6%) | 16/35 (45.7%) |
| Event | Triptorelin Pamoate 11.25 mg |
|---|---|
| Gait disturbanceGeneral disorders | 1/35 |
| Foot fractureInjury, poisoning and procedural complications | 1/35 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/35 |
| Vaginal haemorrhageReproductive system and breast disorders | 1/35 |
| Event | Triptorelin Pamoate 11.25 mg |
|---|---|
| Abdominal painGastrointestinal disorders | 6/35 |
| Injection site painGeneral disorders | 4/35 |
| HeadacheNervous system disorders | 3/35 |
| Hot flushVascular disorders | 3/35 |
| VomitingGastrointestinal disorders | 2/35 |
| InsomniaPsychiatric disorders | 2/35 |
| Pelvic painReproductive system and breast disorders | 2/35 |
| Vaginal haemorrhageReproductive system and breast disorders | 2/35 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/35 |
| Weight increasedInvestigations | 2/35 |
Baseline characteristics are presented for Intention-To-Treat Population (ITT) population, consisting of all enrolled patients who received at least one injection of study treatment in this follow up study. These data were not re-collected at the start of the current study and are derived from data collected at Baseline of study 2-54-52014-143.
| Age, Continuous(years) | Triptorelin Pamoate 11.25 mg |
|---|---|
| Mean | 8.73 ± 1.07 |
| Sex: Female, Male(Participants) | Triptorelin Pamoate 11.25 mg |
|---|---|
| Female | 34 |
| Male | 1 |
| Weight at Pretreatment(kilogram (kg)) | Triptorelin Pamoate 11.25 mg |
|---|---|
| Mean | 32.4 ± 6.9 |
The record gives a start of Apr 2008, a primary completion of Apr 2015 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.
Results were first posted in May 2017, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triptorelin